{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:55:12Z","timestamp":1792716912689,"version":"4.5.0"},"reference-count":57,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T00:00:00Z","timestamp":1673049600000},"content-version":"vor","delay-in-days":128,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T00:00:00Z","timestamp":1655164800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100009128","name":"Research for Patient Benefit programme","doi-asserted-by":"publisher","award":["PB-PG-0110-21244"],"award-info":[{"award-number":["PB-PG-0110-21244"]}],"id":[{"id":"10.13039\/501100009128","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009128","name":"Research for Patient Benefit Programme","doi-asserted-by":"publisher","award":["PB\u2010PG\u20100110\u201021244"],"award-info":[{"award-number":["PB\u2010PG\u20100110\u201021244"]}],"id":[{"id":"10.13039\/501100009128","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The risk of cutaneous squamous cell carcinoma (cSCC) is significantly increased in organ transplant recipients (OTRs). Clearance of actinic keratoses (AKs) is generally regarded as a surrogate biomarker for cSCC prevention. OTR-cSCC chemoprevention with topical AK treatments has not been investigated in randomized controlled trials (RCTs), although there is evidence that 5% 5-fluorouracil (5-FU) may be chemoprotective in immunocompetent patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the feasibility, activity and evaluation outcomes relevant to the design of a future phase III RCT of topical cSCC chemoprevention in OTRs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>OTRs with 10 or more AKs in predefined areas were randomized 1 : 1 : 1 to topical 5-FU, 5% imiquimod (IMIQ) or sunscreen (sun-protective factor 30+) in a phase II, open-label RCT over 15 months. Feasibility outcomes included proportions of eligible OTRs randomized, completing treatment and willing to be re-treated. AK activity [AK clearance, new AK development, patient-centred outcomes (toxicity, health-related quality of life, HRQoL)] and evaluation methodology (clinical vs. photographic) were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty OTRs with 903 AKs were randomized. All feasibility outcomes were met (56% of eligible OTRs were randomized; 89% completed treatment; 81% were willing to be re-treated). AK activity analyses found 5-FU and IMIQ were superior to sunscreen for AK clearance and prevention of new AKs. 5-FU was more effective than IMIQ in AK clearance and prevention in exploratory analyses. Although toxicity was greater with 5-FU, HRQoL outcomes were similar.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Trials of topical AK treatments in OTRs for cSCC chemoprevention are feasible and AK activity results support further investigation of 5-FU-based treatments in future phase III trials.<\/jats:p>\n                    <jats:p>What is already known about this topic? Cutaneous squamous cell carcinoma (cSCC) is significantly more common in immunocompromised individuals including organ transplant recipients (OTRs) compared with immunocompetent populations. cSCC chemoprevention activity of sunscreen and 5-fluorouracil-based (5-FU) actinic keratosis (AK) treatments has been demonstrated in randomized controlled trials (RCTs) in immunocompetent populations but not in OTRs. AKs are cSCC precursors and their clearance and prevention are generally regarded as surrogate endpoint biomarkers for potential cSCC chemoprevention activity.<\/jats:p>\n                    <jats:p>What does this study add? SPOT (SCC Prevention in OTRs using Topical treatments) has confirmed that RCTs of OTR-cSCC chemoprevention with topical AK treatments are feasible. It also suggests that topical 5-FU may be superior to 5% imiquimod and sunscreen in AK clearance and prevention. Together with recent evidence from several RCTs in the general population, these data provide a compelling rationale for further studies of intervention with 5-FU-based topical chemoprevention approaches in OTR-cSCC prevention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bjd.20974","type":"journal-article","created":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T01:53:01Z","timestamp":1641433981000},"page":"324-337","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments)"],"prefix":"10.1093","volume":"187","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3391-2730","authenticated-orcid":false,"given":"Zeeshaan-Ul","family":"Hasan","sequence":"first","affiliation":[{"name":"Department of Dermatology Barts Health NHS Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikhlaaq","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Cancer Research UK Clinical Trials Unit University of Birmingham Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rubeta N.","family":"Matin","sequence":"additional","affiliation":[{"name":"Department of Dermatology Churchill Hospital, Oxford University Hospital NHS Foundation Trust Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Homer","sequence":"additional","affiliation":[{"name":"Cancer Research UK Clinical Trials Unit University of Birmingham Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Lear","sequence":"additional","affiliation":[{"name":"Department of Dermatology Salford Royal NHS Foundation Trust, Salford, UK and Manchester Academic Science Centre, Manchester University UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferina","family":"Ismail","sequence":"additional","affiliation":[{"name":"Royal Free Hospital NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Whitmarsh","sequence":"additional","affiliation":[{"name":"Institute of Astronomy University of Cambridge Madingley Road Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2753-4841","authenticated-orcid":false,"given":"Adele C.","family":"Green","sequence":"additional","affiliation":[{"name":"Cancer Research UK University of Manchester Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Thomson","sequence":"additional","affiliation":[{"name":"Department of Dermatology Barts Health NHS Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Milligan","sequence":"additional","affiliation":[{"name":"Royal Free Hospital NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hogan","sequence":"additional","affiliation":[{"name":"Department of Dermatology Barts Health NHS Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Van-de-Velde","sequence":"additional","affiliation":[{"name":"Department of Dermatology Barts Health NHS Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza","family":"Mitchell-Worsford","sequence":"additional","affiliation":[{"name":"Department of Dermatology Barts Health NHS Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7109-6199","authenticated-orcid":false,"given":"Jonathan","family":"Kentley","sequence":"additional","affiliation":[{"name":"Department of Dermatology Barts Health NHS Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Gaunt","sequence":"additional","affiliation":[{"name":"Cancer Research UK Clinical Trials Unit University of Birmingham Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolande","family":"Jefferson-Hulme","sequence":"additional","affiliation":[{"name":"Cancer Research UK Clinical Trials Unit University of Birmingham Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J.","family":"Bowden","sequence":"additional","affiliation":[{"name":"Cancer Research UK Clinical Trials Unit University of Birmingham Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piers","family":"Gaunt","sequence":"additional","affiliation":[{"name":"Cancer Research UK Clinical Trials Unit University of Birmingham Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Wheatley","sequence":"additional","affiliation":[{"name":"Cancer Research UK Clinical Trials Unit University of Birmingham Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3292-4836","authenticated-orcid":false,"given":"Charlotte M.","family":"Proby","sequence":"additional","affiliation":[{"name":"Jacqui Wood Cancer Centre University of Dundee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine A.","family":"Harwood","sequence":"additional","affiliation":[{"name":"Department of Dermatology Barts Health NHS Trust London UK"},{"name":"Centre for Cell Biology and Cutaneous Research Blizard Institute, Queen Mary University of London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,9,1]]},"reference":[{"key":"2023010808100825700_bjd20974-bib-0001","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/bjd.17873","article-title":"Epidemiology of basal and cutaneous squamous cell carcinoma in the U.K. 2013\u201315: a cohort study","volume":"181","author":"Venables","year":"2019","journal-title":"Br J Dermatol"},{"key":"2023010808100825700_bjd20974-bib-0002","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/bjd.15956","article-title":"The pathogenesis of cutaneous squamous cell carcinoma in organ transplant recipients","volume":"177","author":"Harwood","year":"2017","journal-title":"Br J Dermatol"},{"key":"2023010808100825700_bjd20974-bib-0003","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1001\/jamadermatol.2018.4219","article-title":"Nationwide incidence of metastatic cutaneous squamous cell carcinoma in England","volume":"155","author":"Venables","year":"2019","journal-title":"JAMA Dermatol"},{"key":"2023010808100825700_bjd20974-bib-0004","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.jid.2020.12.024","article-title":"The genomic landscape of actinic keratosis","volume":"141","author":"Thomson","year":"2021","journal-title":"J Invest Dermatol"},{"key":"2023010808100825700_bjd20974-bib-0005","first-page":"830","article-title":"Actinic keratoses, actinic field change and associations with squamous cell carcinoma in renal transplant recipients in Manchester","volume":"95","author":"Wallingford","year":"2015","journal-title":"UK. Acta Derm Venereol"},{"key":"2023010808100825700_bjd20974-bib-0006","doi-asserted-by":"crossref","first-page":"878","DOI":"10.2340\/00015555-3198","article-title":"Sunbed use increases cutaneous squamous cell carcinoma risk in women: a large-scale, prospective study in Sweden","volume":"99","author":"Christensen","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"2023010808100825700_bjd20974-bib-0007","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0140-6736(98)12168-2","article-title":"Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial","volume":"354","author":"Green","year":"1999","journal-title":"Lancet"},{"key":"2023010808100825700_bjd20974-bib-0008","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0140-6736(88)91658-3","article-title":"Malignant transformation of solar keratoses to squamous cell carcinoma","volume":"1","author":"Marks","year":"1988","journal-title":"Lancet"},{"key":"2023010808100825700_bjd20974-bib-0009","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1001\/archderm.139.4.451","article-title":"A randomized controlled trial to assess sunscreen application and beta carotene supplementation in the prevention of solar keratoses","volume":"139","author":"Darlington","year":"2003","journal-title":"Arch Dermatol"},{"key":"2023010808100825700_bjd20974-bib-0010","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1001\/jamadermatol.2017.3631","article-title":"Chemoprevention of basal and squamous cell carcinoma with a single course of fluorouracil, 5%, cream: a randomized clinical trial","volume":"154","author":"Weinstock","year":"2018","journal-title":"JAMA Dermatol"},{"key":"2023010808100825700_bjd20974-bib-0011","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1172\/JCI89820","article-title":"Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy","volume":"127","author":"Cunningham","year":"2017","journal-title":"J Clin Invest"},{"key":"2023010808100825700_bjd20974-bib-0012","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1056\/NEJMoa1811850","article-title":"Randomized trial of four treatment approaches for actinic keratosis","volume":"380","author":"Jansen","year":"2019","journal-title":"N Engl J Med"},{"key":"2023010808100825700_bjd20974-bib-0013","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bjd.17148","article-title":"Local interventions for actinic keratosis in organ transplant recipients: a systematic review","volume":"180","author":"Heppt","year":"2019","journal-title":"Br J Dermatol"},{"key":"2023010808100825700_bjd20974-bib-0014","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bjd.17326","article-title":"\u2018Surprisingly little evidence\u2019 on how best to treat actinic keratosis in organ transplant recipients","volume":"180","author":"Werner","year":"2019","journal-title":"Br J Dermatol"},{"issue":"Suppl. 2","key":"2023010808100825700_bjd20974-bib-0015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2133.2007.08269.x","article-title":"Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients","volume":"157","author":"Ulrich","year":"2007","journal-title":"Br J Dermatol"},{"key":"2023010808100825700_bjd20974-bib-0016","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/j.1365-2133.2006.07454.x","article-title":"Specialist dermatology clinics for organ transplant recipients significantly improve compliance with photoprotection and levels of skin cancer awareness","volume":"155","author":"Ismail","year":"2006","journal-title":"Br J Dermatol"},{"key":"2023010808100825700_bjd20974-bib-0017","first-page":"99","article-title":"Developing a standardized actinic keratosis assessment protocol","volume":"169","author":"Matin","year":"2013","journal-title":"Br J Dermatol"},{"key":"2023010808100825700_bjd20974-bib-0018","author":"US Department of Health and Human Services"},{"key":"2023010808100825700_bjd20974-bib-0019","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI) \u2013 a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"2023010808100825700_bjd20974-bib-0020","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/MLG.0b013e31802e2d88","article-title":"The Skin Cancer Index: clinical responsiveness and predictors of quality of life","volume":"117","author":"Rhee","year":"2007","journal-title":"Laryngoscope"},{"key":"2023010808100825700_bjd20974-bib-0021","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/bjd.16801","article-title":"Patient preferences for topical treatment of actinic keratoses: a discrete-choice experiment","volume":"180","author":"Kopasker","year":"2019","journal-title":"Br J Dermatol"},{"issue":"CD004415","key":"2023010808100825700_bjd20974-bib-0022","article-title":"Interventions for actinic keratoses","volume":"12","author":"Gupta","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2023010808100825700_bjd20974-bib-0023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096829","article-title":"A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe","volume":"9","author":"Vegter","year":"2014","journal-title":"PLoS One"},{"key":"2023010808100825700_bjd20974-bib-0024","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ijpharm.2016.07.043","article-title":"Mechanisms of imiquimod skin penetration","volume":"511","author":"Tel\u00f2","year":"2016","journal-title":"Int J Pharm"},{"key":"2023010808100825700_bjd20974-bib-0025","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1111\/jdv.16857","article-title":"In vivo characterization of healthy human skin with a novel, non-invasive imaging technique: line-field confocal optical coherence tomography","volume":"34","author":"Monnier","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023010808100825700_bjd20974-bib-0026","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaad.2020.03.127","article-title":"Field cancerization: treatment","volume":"83","author":"Cornejo","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2023010808100825700_bjd20974-bib-0027","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1365-2133.2006.07616.x","article-title":"Treatment of post-transplant premalignant skin disease: a randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy","volume":"156","author":"Perrett","year":"2007","journal-title":"Br J Dermatol"},{"key":"2023010808100825700_bjd20974-bib-0028","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/bjd.15884","article-title":"Photodynamic therapy is more effective than imiquimod for actinic keratosis in organ transplant recipients: a randomized intraindividual controlled trial","volume":"178","author":"Togsverd-Bo","year":"2018","journal-title":"Br J Dermatol"},{"key":"2023010808100825700_bjd20974-bib-0029","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/bjd.18884","article-title":"A trial-based cost-effectiveness analysis of topical 5-fluorouracil vs. imiquimod vs. ingenol mebutate vs. methyl aminolaevulinate conventional photodynamic therapy for the treatment of actinic keratosis in the head and neck area performed in the Netherlands","volume":"183","author":"Jansen","year":"2020","journal-title":"Br J Dermatol"},{"key":"2023010808100825700_bjd20974-bib-0030","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1158\/1055-9965.EPI-06-0352","article-title":"Prolonged prevention of squamous cell carcinoma of the skin by regular sunscreen use","volume":"15","author":"van der Pols","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2023010808100825700_bjd20974-bib-0031","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1038\/jid.2009.141","article-title":"Regular sunscreen use is a cost-effective approach to skin cancer prevention in subtropical settings","volume":"129","author":"Gordon","year":"2009","journal-title":"J Invest Dermatol"},{"issue":"Suppl. 3","key":"2023010808100825700_bjd20974-bib-0032","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1365-2133.2009.09453.x","article-title":"Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case\u2013control study","volume":"161","author":"Ulrich","year":"2009","journal-title":"Br J Dermatol"},{"key":"2023010808100825700_bjd20974-bib-0033","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/sj.jid.5700098","article-title":"Photodynamic therapy does not prevent cutaneous squamous-cell carcinoma in organ-transplant recipients: results of a randomized-controlled trial","volume":"126","author":"de Graaf","year":"2006","journal-title":"J Invest Dermatol"},{"key":"2023010808100825700_bjd20974-bib-0034","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/00015550510042868","article-title":"Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients","volume":"86","author":"Wulf","year":"2006","journal-title":"Acta Derm Venereol"},{"key":"2023010808100825700_bjd20974-bib-0035","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/TP.0b013e318180731e","article-title":"Photodynamic therapy with methyl aminolevulinate for prevention of new skin lesions in transplant recipients: a randomized study","volume":"86","author":"Wennberg","year":"2008","journal-title":"Transplantation"},{"key":"2023010808100825700_bjd20974-bib-0036","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1440-0960.2002.00613.x","article-title":"Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients","volume":"43","author":"George","year":"2002","journal-title":"Australas J Dermatol"},{"key":"2023010808100825700_bjd20974-bib-0037","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1067\/S0190-9622(03)01831-0","article-title":"Acitretin treatment of premalignant and malignant skin disorders in renal transplant recipients: clinical effects of a randomized trial comparing two doses of acitretin","volume":"49","author":"de S\u00e9vaux","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"2023010808100825700_bjd20974-bib-0038","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/DSS.0000000000002423","article-title":"Efficacy and cost analysis for acitretin for basal and squamous cell carcinoma prophylaxis in renal transplant recipients","volume":"47","author":"Badri","year":"2021","journal-title":"Dermatol Surg"},{"key":"2023010808100825700_bjd20974-bib-0039","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jaad.2020.04.160","article-title":"Chemoprevention of keratinocyte carcinoma and actinic keratosis in solid-organ transplant recipients: systematic review and meta-analyses","volume":"84","author":"Tee","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2023010808100825700_bjd20974-bib-0040","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/ijd.15442","article-title":"Is the first-line systemic chemoprevention of nonmelanoma skin cancer nicotinamide or acitretin?","volume":"60","author":"Hoegler","year":"2021","journal-title":"Int J Dermatol"},{"key":"2023010808100825700_bjd20974-bib-0041","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJMoa1204166","article-title":"Sirolimus and secondary skin-cancer prevention in kidney transplantation","volume":"367","author":"Euvrard","year":"2012","journal-title":"N Engl J Med"},{"key":"2023010808100825700_bjd20974-bib-0042","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1200\/JCO.2012.45.6376","article-title":"Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus","volume":"31","author":"Hoogendijk-van den Akker","year":"2013","journal-title":"J Clin Oncol"},{"key":"2023010808100825700_bjd20974-bib-0043","first-page":"480","article-title":"Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients","volume":"12","author":"Alter","year":"2014","journal-title":"J Dtsch Dermatol Ges"},{"key":"2023010808100825700_bjd20974-bib-0044","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJMoa1506197","article-title":"A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention","volume":"373","author":"Chen","year":"2015","journal-title":"N Engl J Med"},{"key":"2023010808100825700_bjd20974-bib-0045","volume-title":"Effect of oral nicotinamide on non-melanoma skin cancer incidence and actinic keratosis in renal, hepatic, heart and lung transplant recipients: a randomised controlled trial","author":"Damain"},{"key":"2023010808100825700_bjd20974-bib-0046","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1001\/jamadermatol.2015.0502","article-title":"Long-term efficacy of topical fluorouracil cream, 5%, for treating actinic keratosis: a randomized clinical trial","volume":"151","author":"Pomerantz","year":"2015","journal-title":"JAMA Dermatol"},{"key":"2023010808100825700_bjd20974-bib-0047","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.jid.2016.12.029","article-title":"5-Fluorouracil for actinic keratosis treatment and chemoprevention: a randomized controlled trial","volume":"137","author":"Walker","year":"2017","journal-title":"J Invest Dermatol"},{"key":"2023010808100825700_bjd20974-bib-0048","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.125476","article-title":"Skin cancer precursor immunotherapy for squamous cell carcinoma prevention","volume":"4","author":"Rosenberg","year":"2019","journal-title":"JCI Insight"},{"key":"2023010808100825700_bjd20974-bib-0049","first-page":"1055","article-title":"Reliability of counting actinic keratoses before and after brief consensus discussion: the VA Topical Tretinoin Chemoprevention (VATTC) trial","volume":"137","author":"Weinstock","year":"2001","journal-title":"Arch Dermatol"},{"key":"2023010808100825700_bjd20974-bib-0050","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/00128071-200405030-00001","article-title":"Quantifying actinic keratosis: assessing the evidence","volume":"5","author":"Epstein","year":"2004","journal-title":"Am J Clin Dermatol"},{"key":"2023010808100825700_bjd20974-bib-0051","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/bjd.12591","article-title":"Reliability of quantification measures of actinic keratosis","volume":"169","author":"Chen","year":"2013","journal-title":"Br J Dermatol"},{"key":"2023010808100825700_bjd20974-bib-0052","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/bjd.12629","article-title":"Improvement in precision of counting actinic keratoses","volume":"170","author":"Lee","year":"2014","journal-title":"Br J Dermatol"},{"key":"2023010808100825700_bjd20974-bib-0053","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2340\/00015555-2783","article-title":"Incidence and regression of actinic keratoses in organ transplant recipients","volume":"98","author":"Jiyad","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"2023010808100825700_bjd20974-bib-0054","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/jdv.14267","article-title":"A proposed scoring system for assessing the severity of actinic keratosis on the head: actinic keratosis area and severity index","volume":"31","author":"Dirschka","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023010808100825700_bjd20974-bib-0055","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2340\/00015555-2710","article-title":"A novel actinic keratosis field assessment scale for grading actinic keratosis disease severity","volume":"97","author":"Dr\u00e9no","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"2023010808100825700_bjd20974-bib-0056","doi-asserted-by":"crossref","first-page":"604","DOI":"10.2340\/00015555-2040","article-title":"Counting actinic keratosis \u2013 is photographic assessment a reliable alternative to physical examination in clinical trials?","volume":"95","author":"Sinnya","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"2023010808100825700_bjd20974-bib-0057","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2340\/00015555-2539","article-title":"Assessing the concordance of actinic keratosis counts on digital photographs with clinical examination in organ transplant recipients","volume":"97","author":"Jiyad","year":"2017","journal-title":"Acta Derm Venereol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjd.20974","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjd.20974","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/187\/3\/324\/48528820\/bjd0324.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/187\/3\/324\/48528820\/bjd0324.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T06:37:06Z","timestamp":1700030226000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/187\/3\/324\/6966583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":57,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,9,1]]},"published-print":{"date-parts":[[2022,9,1]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.20974","relation":{},"ISSN":["1365-2133","0007-0963"],"issn-type":[{"value":"1365-2133","type":"electronic"},{"value":"0007-0963","type":"print"}],"subject":[],"published-other":{"date-parts":[[2022,9,1]]},"published":{"date-parts":[[2022,9,1]]},"assertion":[{"value":"2021-09-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}